Based on the Kymera Therapeutics Inc stock forecast from 11 analysts, the average analyst target price for Kymera Therapeutics Inc is USD 56.00 over the next 12 months. Kymera Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Kymera Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Kymera Therapeutics Inc’s stock price was USD 25.02. Kymera Therapeutics Inc’s stock price has changed by +4.47% over the past week, -27.20% over the past month and -26.26% over the last year.
No recent analyst target price found for Kymera Therapeutics Inc
No recent average analyst rating found for Kymera Therapeutics Inc
Company Overview Kymera Therapeutics Inc
Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Read Less
Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system...Read More
Frequently Asked Questions About Kymera Therapeutics Inc (KYMR) Stock
Based on ratings from 11 analysts Kymera Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on KYMR's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for KYMR is USD 56.00 over the next 12 months. The maximum analyst target price is USD 65 while the minimum anlayst target price is USD 41.
Unfortunately we do not have enough data on KYMR's stock to indicate if its overvalued.
The last closing price of KYMR's stock was USD 25.02.
The most recent market capitalization for KYMR is USD 1.57B.
Based on targets from 11 analysts, the average taret price for KYMR is projected at USD 56.00 over the next 12 months.
This means that KYMR's stock price may go up by +123.82% over the next 12 months.
We can't find any ETFs which contains Kymera Therapeutics Inc's stock.
As per our most recent records Kymera Therapeutics Inc has 188 Employees.
Kymera Therapeutics Inc's registered address is 500 North Beacon Street, Watertown, MA, United States, 02472.
You can get more information about it from Kymera Therapeutics Inc's website at https://www.kymeratx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Kymera Therapeutics Inc (KYMR) Stock
Based on ratings from 11 analysts Kymera Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on KYMR's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for KYMR is USD 56.00 over the next 12 months. The maximum analyst target price is USD 65 while the minimum anlayst target price is USD 41.
Unfortunately we do not have enough data on KYMR's stock to indicate if its overvalued.
The last closing price of KYMR's stock was USD 25.02.
The most recent market capitalization for KYMR is USD 1.57B.
Based on targets from 11 analysts, the average taret price for KYMR is projected at USD 56.00 over the next 12 months.
This means that KYMR's stock price may go up by +123.82% over the next 12 months.
We can't find any ETFs which contains Kymera Therapeutics Inc's stock.
As per our most recent records Kymera Therapeutics Inc has 188 Employees.
Kymera Therapeutics Inc's registered address is 500 North Beacon Street, Watertown, MA, United States, 02472.
You can get more information about it from Kymera Therapeutics Inc's website at https://www.kymeratx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for KYMR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
